Recent Updates
Recently added Catalysts
NKTX

Nkarta Announces June 2021 Investor Conference Schedule

Key Takeaway: SOUTH SAN FRANCISCO, Calif., May 25, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced its participation at this upcoming investor conference: Jefferies Virt

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+124%
120-day peak, hindsight
Typical move
7.6%
average across 3 past catalysts
Cash runway
~22 mo
Low dilution risk
Lead asset
NKX101- CAR NK cell therapy
Phase 1 · Relapsed/Refractory AML

Full Press Release Details

SOUTH SAN FRANCISCO, Calif., May 25, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced its participation at this upcoming investor conference:
Jefferies Virtual Healthcare Conference
Fireside chat presentation: 3:30 p.m. ET
The live webcast of the presentation will be available on the Investors section of Nkarta’s website, www.nkartatx.com. A replay of the webcast will be archived on the website for approximately four weeks.
Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off the shelf natural killer (NK) cell therapies for cancer. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies, Nkarta is building a pipeline of cell therapy candidates generated by efficient manufacturing processes, which are engineered to enhance tumor targeting and improve persistence for sustained activity in the body. For more information, please visit www.nkartatx.com.
Nkarta Media/Investor Contact:
Last updated: May 25, 2021